Webinar: Introducing HµRELTM: “Plug-and-Play” Primary Hepatic Models for In Vitro DMPK and Safety Applications –     Watch Webinar    
Presented by Hurel’s former Chief Scientific Officer Dr. Eric Novik, providing an overview of the following topics:

  1. Hurel’s multi-week window of stable cellular competency
  2. HµRELhumanPoolTM: a pre-launch look. Combining the pheonotypic breadth of pooled primary hepatocytes with the stable, long-enduring cellular compentency of Hurel
  3. Using Hurel’s co-culture models for Drug Metabolism studies, including metabolite generation, clearance of low-turnover compounds, and long-term inhibition.
  4. Using Hurel for relevant prediction of in vitro toxicity, incliuding in long-term and repeat dose-experiments.
  5. Differences and advantages of Hurel compared to other cell-based hepatic models






HµRELToxTM
multi-readout, repeat-dose
DILI screening
DILI screening

Hurel microlivers afford better prediction than 3D

Toxicology Research
HµRELviralTM
Long-enduring infectious liver disease platform
Time-Based
Toxicity Ratios*
A new marker for hepatotoxic chronicity

TAAP
*patent pending
HµRELfluxTM
a new, patent-pending
efflux transport
assay method
DMPK
Superior intrinsic clearance
and biotransformation of
low-turnover drugs

DMD